BCG’s John Wong tells Bloomberg that the prospect of faster drug approvals in the healthcare industry has potential to drive multinationals to bring more of their innovations to China.
BCG uses cookies to improve the functionality, performance, and
effectiveness of our communications. Detailed information on the use of cookies is provided in our Privacy
Policy. By continuing to use this site, or by clicking "I agree," you consent to the use of cookies.
